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Gene encoding flavin-containing monooxygenase 3 (FMO3), a microsomal antioxidant defense enzyme, has been suggested
to contribute to essential hypertension (EH). The present study was designed to investigate whether common functional
polymorphism E158K (rs2266782) of the FMO3 gene is associated with EH susceptibility in a Russian population. A total of 2 995
unrelated subjects from Kursk (1 362 EH patients and 843 healthy controls) and Belgorod (357 EH patients and 422 population
controls) regions of Central Russia were recruited for this study. DNA samples from all study participants were genotyped for the
FMO3 gene polymorphism through PCR followed by RFLP analysis. We found that the polymorphism E158K is associated with
increased risk of essential hypertension in both discovery population from Kursk region (OR 1.36 95% CI 1.09–1.69, 𝑃 = 0.01) and
replication population fromBelgorod region (OR 1.54 95%CI 1.07–1.89,𝑃 = 0.02) after adjustment for gender and age using logistic
regression analysis. Further analysis showed that the increased hypertension risk in carriers of genotype 158KK gene occurred in
cigarette smokers, whereas nonsmoker carriers of this genotype did not show the disease risk. This is the first study reporting the
association of the FMO3 gene polymorphism and the risk of essential hypertension.
1. Introduction
Oxidative stress resulting from the enhanced production
of reactive oxygen species (ROS) and decreased activity
of antioxidant defense enzymes has been implicated in
pathogenesis of essential hypertension (EH) [1, 2]. The
flavin-containing monooxygenase 3 (FMO3) is a microso-
mal antioxidant defense enzyme involving the NADPH-
dependent oxygenation of a variety of nucleophilic xeno-
biotics possessing oxidant capacity [3]. Mutations in the
FMO3 gene have been found to contribute to the dis-
ease trimethylaminuria (TMAuria), an inborn error of
metabolism resulting from diminished oxidation of the
tertiary amine trimethylamine to trimethylamine N-oxide
resulting in a severe body odour in affected individuals [4].
Interestingly, this genetic disorder is thought to be associated
with risk of hypertension because patients with TMAuria
have idiopathic hypertension [4, 5].
A single study investigated the relationship between com-
mon polymorphisms of the FMO3 gene and hypertension in
Irish population [6]. However, these researchers found that
none of the FMO3 gene polymorphisms was associated with
hypertension risk. This negative result can be explained by a
relatively low statistical power which is related with a small
sample size in the study. The present study was designed
to investigate whether common functional polymorphism
E158K (rs2266782) of the FMO3 gene is associated with
susceptibility to essential hypertension in Russia. Pursuing
this aim, two independent populations of ethnic Russians
from Kursk and Belgorod regions of Central Russia were
included in this study to be used as discovery and replication
cohorts, respectively.
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Table 1: Baseline characteristics of two study populations.
Baseline characteristics EH patients Controls 𝑃 values
Discovery cohort (Kursk region): 1 362 EH patients and 843 healthy subjects
Age, mean ± standard deviation 56.4 ± 10.4 55.8 ± 8.8 0.18
Gender
(M-male, F-female)
711 M (52.2%)
651 F (47.8%)
406 M (48.2%)
437 F (51.8%) 0.07
Body mass index
(kg/m2), mean ± standard deviation 27.3 ± 6.5 26.2 ± 5.9 0.002
∗
Family history
of hypertension
Yes 764 (65.9%)
No 395 (34.1%)
Yes 414 (57.8%)
No 302 (42.2%) 0.0004
∗
Smoking status Yes 841 (67.4%)No 406 (32.6%)
Yes 483 (61.9%)
No 297 (38.1%) 0.01
∗
Replication cohort (Belgorod region): 357 EH patients and 422 population controls
Age, mean ± standard deviation 58.4 ± 9.5 57.3 ± 10.2 0.12
Gender
(M-male, F-female)
211 M (59.1%)
146 F (40.9%)
267 M (63.3%)
155 F (36.7%) 0.23
Body mass index
(kg/m2), mean ± standard deviation 26.2 ± 4.8 25.6 ± 3.9 0.07
Family history
of hypertension NA NA —
Smoking status NA NA —
∗Means a significant difference between the groups.
2. Materials and Methods
The study was approved by Ethical Review Committee of
Kursk State Medical University. A total of 2 995 Russian
unrelated subjects from Kursk (discovery cohort) and Bel-
gorod (replication population) regions of Central Russia
were included in the study. The discovery cohort comprising
2 216 subjects (1 362 EH patients and 843 healthy subjects
with normal blood pressure) was recruited at Cardiology
Clinics of Kursk Regional Clinical Hospital and Neurology
Clinics of Kursk Emergency Medicine Hospital over two
periods: between 2003 and 2006 [7] and between 2010 and
2013. The replication population included DNA samples
from 779 individuals (357 EH patients and 422 population
controls) which have been obtained from the biobank of
Belgorod State National Research University, as part of a
large population-based study of Belgorod region [8]. The
baseline characteristics of the study patients are listed in
Table 1. As can be seen from Table 1, hypertensive patients
were matched to controls on sex and age (𝑃 > 0.05).
Diagnosis of essential hypertension in both populations was
verified by qualified cardiologists. Individuals were defined
as hypertensive according to World Health Organization
criteria or if they had a history of receiving any antihy-
pertensive drug. Diagnosis of EH in untreated patients was
defined by a seated systolic and/or diastolic blood pressure
greater than 140 and/or 90mmHg, respectively, on at least 2
separatemeasurements. All EH patients had no clinical signs,
symptoms, and laboratory findings suggestive of secondary
hypertension.
Genomic DNA was isolated from peripheral blood sam-
ples using a standard phenol/chloroform procedure. Geno-
typing of polymorphism E158K of the FMO3 gene was done
using PCR followed by RFLP analysis as described elsewhere
[9]. The genotyping results were scored by two independent
investigators blindly to the patient’s case/control status and
regenotyping of about 5% of randomly selected samples
yielded 100% reproducibility.
The association between the polymorphism and hyper-
tension risk was estimated by odds ratio (OR) with 95%
confidence interval (CI) using multiple logistic regression
analysis with adjustment for confounding variables such as
age and gender. Each FMO3 genotype was assessed according
to dominant, recessive, and additive genetic models, and the
chi-squire (Wald’s statistic) odds ratio with 95% confidence
interval was calculated. Odds ratios were calculated as a
measure of the association of the FMO3 genotype with
hypertension risk, with the effects of the allele 158K assumed
to be additive (with scores of 0, 1, and 2 assigned for EE,
EK, and KK genotypes, resp.), dominant (with scores of 0
for EE genotype and 1 for EK and KK genotypes combined),
or recessive (with scores of 0 for EE and EK genotypes
combined and 1 for KK genotype). The statistical signifi-
cance was established at P ≤ 0.05. Bonferroni correction
for 𝑃 values (𝑃adj) was applied in cases when multiple
tests were performed. Statistical calculations were performed
with Statistica for Windows 8.0 (StatSoft Inc., Tulsa, OK,
USA).
3. Results and Discussion
As can be seen from Table 1, a percentage of positive family
history of hypertension and cigarette smokers in the dis-
covery cohort (these data were available only from Kursk
population) was significantly greater in patients with EH ver-
sus healthy controls. Body mass index in hypertensives was
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Table 2: Allele and genotype frequencies for polymorphism E158K of the FMO3 gene in patients with essential hypertension (EH) and
controls in two Russian populations.
FMO3 allele and
genotype
frequencies
EH patients
𝑁 (%)I
Controls
𝑁 (%)I
Chi-square
(𝑃)II
OR
(95% CI)
Discovery cohort (Kursk region),𝑁 = 2216 (1 362 EH patients and 843 healthy controls)
Alleles
158E
158K
1 474 (54.1)
1 250 (45.9)
960 (56.2)
748 (43.8)
1.86 (0.17)
df = 1 1.09 (0.96–1.23)
III
Genotypes
158EE
158EK
158KK
423 (31.1)
628 (46.1)
311 (22.8)
260 (30.4)
440 (51.5)
154 (18.0)
9.02 (0.01)∗
df = 2
1.35 (1.08–1.69)III
1.36 (1.09–1.69)IV
Replication population (Belgorod region),𝑁 = 779 (357 EH patients and 422 healthy controls)
Alleles
158E
158K
365 (51.1)
349 (48.9)
468 (55.5)
476 (44.5)
2.91 (0.09)
df = 1 1.19 (0.97–1.45)
III
Genotypes
158EE
158EK
158KK
105 (29.4)
155 (43.4)
97 (27.2)
127 (30.1)
214 (50.7)
81 (19.2)
7.59 (0.02)∗
df = 2
1.57 (1.12–2.00)III
1.54 (1.07–1.89)IV
IAbsolute number and percentage of individuals with particular allele/genotype.
IIPearson’s chi-square statistics and 𝑃 values.
IIIOdds ratio (95% confidence interval) for association between 158KK genotype and EH risk.
IVOdds ratio (95% confidence interval) for association between 158KK genotype and EH risk adjusted for gender and age.
∗Means a significant association.
Table 3: The FMO3 genotype cigarette smoking interaction and susceptibility to essential hypertension in Kursk population.
FMO3
genotype
EH patients
𝑁 (%)
Controls
𝑁 (%) OR (95% CI)
Smokers
(𝑁 = 841)
Nonsmokers
(𝑁 = 406)
Smokers
(𝑁 = 483)
Nonsmokers
(𝑁 = 297) Smokers Nonsmokers
158KK 198 (23.5) 93 (22.9) 88 (18.2) 57 (19.2) 1.38(1.04–1.83)∗
1.25
(0.83–1.81)
∗Means a statistically significant association (𝑃 = 0.023) after adjustment for multiple tests (𝑃adj = 0.046).
higher than that in controls in both cohorts, but the difference
in this parameter did not reach a statistical significance in
Belgorod population (Table 1).
The FMO3 genotype frequencies were in agreement with
Hardy-Weinberg equilibrium (HWE) in control groups from
both populations (𝑃 > 0.05). However, the genotype frequen-
cies in hypertensive groups from both Kursk and Belgorod
populations showed a deviation from HWE (𝑃 < 0.05) due
to a decreased heterozygosity. Data on allele and genotype
frequencies in Kursk and Belgorod populations are shown in
Table 2. No significant difference in the allele 158K frequency
was found between EH patients and controls in both cohorts.
Allele and genotype frequencies were compatible with those
reported previously in Kursk population [9]. Meanwhile,
a statistically significant difference in the distribution of
the FMO3 genotypes was observed between the case and
control groups of Kursk population (𝑃 = 0.01, df = 2).
A statistically significant difference in the distribution of
the FMO3 genotypes between the case and control groups
was also observed in Belgorod population (𝑃 = 0.02). The
genotype 158KK was found to be associated with increased
risk of hypertension in both Kursk and Belgorod populations
after adjustment for gender and age using multiple logistic
regression analysis.
Logistic regression analysis revealed that additive (Wald’s
chi-square = 1.81, 𝑃 = 0.18) and dominant (Wald’s chi-
square = 0.09, 𝑃 = 0.76) genetic models did not show
a significant effect of the FMO3 gene polymorphism on
hypertension risk. Meanwhile, recessive model of the genetic
association between the polymorphism and hypertension
risk was established to be statistically significant (Wald’s chi-
square = 7.28, 𝑃 = 0.007, 𝑃adj = 0.02).
Data on the analysis for the FMO3 genotype-cigarette
smoking interaction and susceptibility to essential hyperten-
sion in Kursk population are shown in Table 3. The gene-
smoking interaction analysis has revealed that genotype
158KK was associated with increased risk of hypertension
only in smokers (OR = 1.38 95% CI 1.04–1.83, 𝑃 = 0.023,
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𝑃adj = 0.046), whereas nonsmoker carriers of the genotype
did not show the disease risk (OR = 1.25 95% CI 0.86–1.81,
𝑃 = 0.24).
We can suggest two possible mechanisms by which the
FMO3 gene polymorphism contributes to the development of
essential hypertension. Firstly, it is known that an amino acid
substitutionGlu-to-Lys at a position 158 (i.e., E158K polymor-
phism) is associated with decreased activity of the enzyme in
oxidation of catecholamine releasing agents such as tyramine,
phenylethylamine, adrenaline, and noradrenaline possessing
vasopressor effects [6, 10]. This means that the low enzyme
activity in carriers of the FMO3 gene variant may be respon-
sible for decreased catabolism of the vasoactive hormones,
thereby contributing to hypertension risk through increased
vasoconstriction and heart rate modulation. Secondly, a
diminished activity of FMO3 in carriers of genotype 158KK
may enhanceROS generation and induce oxidative stress, one
of the proposed pathogenetic mechanisms of human hyper-
tension [1, 2, 11–13]. Furthermore, we found that cigarette
smoking strengthened the risk of essential hypertension
in individuals with genotype 158KK. Notably, the effect of
tobacco smoking on hypertension risk is mediated through
the stimulation of the sympathetic nervous system [14],
enhancing ROS generation and oxidative stress [15], that is,
processes with which flavin-containing monooxygenase 3 is
tightly related.
4. Conclusions
The present study demonstrated for the first time that the
FMO3 gene polymorphism is associated with susceptibility to
essential hypertension, the result which was originally found
in Kursk population and then validated in an independent
population from Belgorod region. We also observed in the
Kursk population that the increased risk of hypertension
in carriers of heterozygous genotype 158KK of the FMO3
gene occurs only in smokers, whereas nonsmokers possessing
this genotype do not have the risk of the disease. This
finding is an indication of the gene-environment interaction,
a situation when adverse effects of cigarette smoking on
hypertension can be enhanced by the phenotypic effects of the
FMO3 polymorphism. Althoughmuch remains to be learned
regarding the biological basis of the relationship between
the FMO3 gene and hypertension risk, it is already clear
that further studies focusing on the investigation of gene-
environment interactions may improve our understanding of
the disease pathogenesis and define novel therapeutic and
preventive options as a means of personalized medicine in
cardiologic practice.
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